(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors.
The Board has accepted the resignation of Mr. Sylwester Cacek’s as director of the Company, effective October 9, 2019. In his place, the Board is pleased to announce the appointment of Mr. Ireneusz Fąfara to the Company’s Board.